Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmathen s.a., grécko - dimetyl-fumarát - 59 - immunopraeparata

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - viacnásobný myelóm - antineoplastické činidlá - empliciti je indikovaný v kombinácii s lenalidomide a dexamethasone pre liečbu myelómom je mladších dospelých pacientov, ktorí dostali aspoň jeden pred liečby (pozri časť 4. 2 a 5.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresíva - pozrite si dokument s informáciami o produkte.

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o. - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o., slovensko - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o., slovensko - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

merck europe b.v. - cladribine - roztrúsená skleróza - imunosupresíva - liečba dospelých pacientov s vysoko aktívnou recidivujúcou sklerózou multiplex (ms), ako je definované klinickými alebo zobrazovacími znakmi.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odmietnutie štepu - imunosupresíva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

noridem enterprises ltd., cyprus - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)